Impact of randomized clinical trials on therapy of primary breast cancer: The NSABP overview
- 30 September 1982
- journal article
- Published by Elsevier in Controlled Clinical Trials
- Vol. 3 (3) , 209-225
- https://doi.org/10.1016/0197-2456(82)90007-1
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes. A southwest oncology group studyCancer, 1982
- Treatment of Primary Breast Cancer with Chemotherapy and TamoxifenNew England Journal of Medicine, 1981
- Dose-Response Effect of Adjuvant Chemotherapy in Breast CancerNew England Journal of Medicine, 1981
- The contribution of recent nsabp clinical trials of primary breast cancer therapy to an understanding of tumor biology—an overview of findingsCancer, 1980
- L-phenylalanine mustard (L-PAM) in the management of primary breast cancer:An update of earlier findings and a comparison with those utilizing L-PAM plus 5-fluorouracil (5-FU)Cancer, 1977
- L-Phenylalanine Mustard (L-PAM) in the Management of Primary Breast CancerNew England Journal of Medicine, 1975
- Anti-oestrogen Therapy for Breast Cancer: A Trial of Tamoxifen at Two Dose LevelsBMJ, 1973
- A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474British Journal of Cancer, 1971
- Surgical Adjuvant Chemotherapy in Cancer of the BreastAnnals of Surgery, 1968
- THE RESULTS OF RADICAL OPERATIONS FOR THE CURE OF CARCINOMA OF THE BREAST.*Annals of Surgery, 1907